Genzyme rare-disease drug gets priority label

Share this article:

The FDA granted priority review status to Genzyme's experimental, all-oral Gaucher's disease treatment Cerdelga (eliglustat).

The FDA's priority label means the regulator will decide for or against the twice-a-day pill within six months.

The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher's disease.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.